Senate Democrats were 1 vote short of overturning the Trump administration's expansion of short-term health plans; Celltrion’s CT-P10, a biosimilar to cancer drug Rituxan, received the unanimous support of an FDA advisory panel; Centene will enter 4 new states—North Carolina, Pennsylvania, South Carolina, and Tennessee—and expand offerings in 10 markets in 2019.
Democrats forced a vote on the Trump administration’s expansion of short-term health insurance plans that do not have to comply with Affordable Care Act (ACA) regulations. However, they fell short of overturning the expansion of these plans by just 1 vote, according to The Washington Post. Democrats voted unanimously to overturn the administration rule and also brought in a vote from Senator Susan Collins, R-Maine, but they would have needed a second Republican vote in order to pass the legislation. In addition, President Donald Trump had already threatened to veto the measure if it reached his desk.
Celltrion’s CT-P10, a biosimilar to cancer drug Rituxan, received the unanimous support of an FDA advisory panel. Reuters reported that the panel ruled Celltrion’s biosimilar was highly similar to the reference biologic. In February, the FDA had declined to approve the proposed biosimilar, citing a manufacturing issue. The FDA usually follows the advice of its advisory panels.
As more insurers are able to find profits in the ACA marketplaces, they have been expanding their participation. Insurer Centene will enter 4 new states—North Carolina, Pennsylvania, South Carolina, and Tennessee—and expand offerings in 10 markets in 2019, according to Fierce Healthcare. The company had increased revenue 13% at the end of the first quarter in 2018. In June, Molina Healthcare and Oscar Insurance reported they were entering new states.
Health Equity and Access Weekly Roundup: December 2, 2023
December 2nd 2023The Center on Health Equity and Access highlights the most recent updates in the realm of health equity, including news, research findings, and initiatives focused on mitigating health care disparities and enhancing overall access to quality care.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More